Zytiga Evropska unija - slovenščina - EMA (European Medicines Agency)

zytiga

janssen-cilag international n.v. - abirateron acetat - prostatične neoplazme - endokrini terapija - zytiga je označena z prednizon ali prednizolon za:zdravljenje metastatskega kastracije odporne raka na prostati pri odraslih moških, ki so asimptomatsko ali lahko simptomatsko po okvari androgen odvzem terapije, pri katerih kemoterapijo še ni klinično indicatedthe zdravljenje metastatskega kastracije odporne raka na prostati pri moških odraslih, katerih bolezen je napredovala na ali po docetaxel temelji kemoterapijo režim.

Poteligeo Evropska unija - slovenščina - EMA (European Medicines Agency)

poteligeo

kyowa kirin holdings b.v. - mogamulizumab - sezary syndrome; mycosis fungoides - antineoplastična sredstva - poteligeo je indiciran za zdravljenje odraslih bolnikov z mycosis fungoides (mf) ali sézary sindrom (ss), ki so prejeli vsaj eno predhodno sistemsko terapijo.

Abiraterone Accord Evropska unija - slovenščina - EMA (European Medicines Agency)

abiraterone accord

accord healthcare s.l.u. - abirateron acetat - prostatične neoplazme - endokrini terapija - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Verquvo Evropska unija - slovenščina - EMA (European Medicines Agency)

verquvo

bayer ag - vericiguat - odpoved srca - srčna terapija - treatment of symptomatic chronic heart failure.

Abiraterone Mylan Evropska unija - slovenščina - EMA (European Medicines Agency)

abiraterone mylan

mylan ireland limited - abirateron acetat - prostatične neoplazme - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Abiraterone Krka Evropska unija - slovenščina - EMA (European Medicines Agency)

abiraterone krka

krka, d.d., novo mesto - abirateron acetat - prostatične neoplazme - endokrini terapija - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Akeega Evropska unija - slovenščina - EMA (European Medicines Agency)

akeega

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatic neoplazem, kastracija-odporne - antineoplastična sredstva - treatment of adult patients with prostate cancer.

Pombiliti Evropska unija - slovenščina - EMA (European Medicines Agency)

pombiliti

amicus therapeutics europe limited - cipaglucosidase alfa - bolezen tipa ii za shranjevanje glikogena - drugi zdravljene bolezni prebavil in presnove izdelki, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).